Biotech and Pharmaceuticals Pharmaceuticals

More

  • *Deal valued at $9.9 bln, including debt. Feb 10- Generic drugmaker Mylan NV said it would buy Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company. Chief Executive Heather Bresch said on a conference call that the company was looking at doing more M&A deals.

  • NEW DELHI, Feb 11- India, concerned at being sidelined from the U.S.-led Trans-Pacific Partnership, is stepping up efforts to reach agreement with an alternative trade bloc centred around China, and hopes to reach a deal this year. Prime Minister Narendra Modi has backed an export-focused' Make in India' drive as the path to prosperity for Asia's third-largest...

  • Mylan to buy Sweden's Meda AB for $7.2 billion Wednesday, 10 Feb 2016 | 4:54 PM ET

    NEW YORK— Drugmaker Mylan says it will buy Meda AB of Sweden for $7.2 billion in cash and stock, and says the move will help it enter new markets. Mylan had $9.45 billion in revenue in 2015 and said Meda's revenue totaled about $2.35 billion. Mylan said the Meda deal will expand its over-the-counter drug business to about $1 billion in annual sales and will bring its...

  • Feb 10- Generic drugmaker Mylan NV said it would buy Sweden's Meda AB in a deal valued at $9.9 billion, including debt. Net income attributable to shareholders rose to $194.6 million, or 38 cents per share, from $192.8 million, or 47 cents per share. On a per-share basis, profit fell to 38 cents per share from 47 cents per share a year earlier due to an increase in the...

  • Mylan says to buy Sweden's Meda Wednesday, 10 Feb 2016 | 4:12 PM ET

    Feb 10- Generic drug maker Mylan NV said it would buy Sweden's Meda AB for about $9.9 billion, including debt, in a combination of cash and stock.

  • *Health Ministry considering increasing prices of finished drugs. CAIRO, Feb 10- Nahed Ibrahim has scoured Egypt in vain to find a regular supply of medication to help her mother to recover from a stroke she suffered four months ago, since then the 75- year-old has struggled to follow conversations. A weaker currency has also made it more expensive to import raw...

  • The FDA usually, but not always, follows the advice of its advisory panels. But the FDA has previously determined it may be appropriate to license biosimilars for additional conditions for which a branded product is approved, even if the biosimilar has not been tested for them. Steven Solga, head of gastroenterology at St. Luke's University Hospital in Bethlehem,...

  • Ghostface Killah fires back at Martin Shkreli Tuesday, 9 Feb 2016 | 12:23 PM ET
    Rapper Ghostface Killah of the Wu-Tang Clan

    The Wu-Tang Clan rapper has recorded a video smackdown of pharma bad boy Shkreli.

  • The news sent shares of J&J, whose annual Remicade sales of $6.5 billion are mostly in the United States, down almost 4 percent. FDA scientists released their favorable report ahead of a meeting Tuesday of an independent medical advisory panel to the agency. "The data submitted by Celltrion show that is highly similar to U.S.-licensed Remicade" in treating...

  • *Forecast for 2016 profit growth defies analyst expectations. *Sees significant income from Uptravi after January launch. ZURICH, Feb 9- Actelion, Europe's largest biotechnology company, forecast that its core earnings would grow in 2016, defying concerns about rising generic competition in its main pulmonary arterial hypertension drug business.

  • Sanofi reports flat 2015 earnings Tuesday, 9 Feb 2016 | 4:31 AM ET

    PARIS— French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes. Sanofi made 4.29 billion euros last year, compared to 4.39 billion in 2014. In December Sanofi and German pharmaceutical company Boehringer Ingelheim said...

  • Rio Olympics: Zika scare sparks warnings Tuesday, 9 Feb 2016 | 3:53 AM ET
    Aedes aegypti mosquitos known to carry the Zika virus.

    Kenya could pull out of this year's Rio Olympics due to concerns over the Zika virus outbreak in Brazil, the head of Kenya's Olympics committee said.

  • 2015 has been a fantasic year: Actelion CEO Tuesday, 9 Feb 2016 | 1:28 AM ET
    2015 has been a fantasic year: Actelion CEO

    Jean-Paul Clozel, CEO of Actelion, says 2015 may be the company's best year, with sales crossing 2 billion Swiss francs thanks to the drug Opsumit.

  • Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. presidential candidates for the November 2016 election. The agreement applies to Cigna's commercial business and does not apply to its Medicaid or Medicare plans. Entresto, which costs...

  • NEW YORK, Feb 8- Pernix Therapeutics Holdings Inc, a U.S. specialty pharmaceutical company, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday. The Morristown, New Jersey- based drugmaker is working with investment bank Perella Weinberg Partners LP, the people said. Pernix shares jumped as much as 17...

  • Feb 8- Pernix Therapeutics Holdings Inc, a U.S. specialty pharmaceutical company, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday. The Morristown, New Jersey- based drugmaker is working with investment bank Perella Weinberg Partners LP, the people said. The process is still in its early stages and...

  • *Drug fails to beat placebo in mid-stage trial. Feb 8- BioCryst Pharmaceuticals Inc said its lead drug failed to reduce the frequency of recurrent swelling in patients with hereditary angioedema, sending its shares skidding as much as 68 percent in early trading on Monday. The results will clearly work in the favor of British drugmaker Shire Plc, which has two...

  • Feb 5- A federal judge on Friday said Allergan Plc's planned generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. They closed up $2.00, or 19.7 percent, at $12.13 on the Nasdaq. District Judge Renée Marie Bumb in Camden, New Jersey said Allergan's proposed generic infringed two of the three Supernus...

  • Supernus beats Allergan over epilepsy drug patents Friday, 5 Feb 2016 | 3:32 PM ET

    Feb 5- A federal judge on Friday said Allergan Plc's plan to sell a generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc.. District Judge Renée Marie Bumb in Camden, New Jersey said the proposed generic version of Oxtellar XR infringed two of three Supernus patents in question. In afternoon trading,...

  • The news sent shares of J&J, whose annual Remicade sales of $6.5 billion are mostly in the United States, down more than 3 percent. FDA scientists released their favorable report ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency. "In considering the totality of the evidence, the data submitted by Celltrion show that is...